LDN is an off label use of naltrexone, a medication that is FDA approved for opioid dependence or alcohol dependence, as it is a strong opioid antagonist. For its approved FDA use, Naltrexone is dosed 50 to 300mg/day. Low dose naltrexone uses 0.5 to 4.5mg typically.
The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD in the 80’s while treating HIV patients.
Out of suffering have emerged the strongest souls; the most massive characters are seared with scars.